Iranian Journal of Pathology

Efforts Focused on Fatty Liver over Two Years (2023-2025): A Thematic Literature Review

Document Type : Review Article

Authors

Mahdi Abdorrashidi 1
Mohammad Hossein Peypar 1
Amirmohammad Tohidinia 1
Fatemeh Zali 1
Sobhan Eisazadeh 1
Mohammad Ali Abyazi 2
Mohammad Heiat 2

1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

https://doi.org/10.30699/ijp.2025.2047720.3391
Abstract
Background & Objective: Nonalcoholic fatty liver disease, recently recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), is a key factor in the development of chronic liver disease and the progression of liver fibrosis. It plays a significant role in increasing the risk of cirrhosis and hepatocellular carcinoma. Given the rapid developments in this field, keeping information up-to-date is essential to prevent misconceptions and ineffective decision-making. This study employs a scientometric approach to review scientific literature and analyze recent findings, offering a comprehensive overview of the current state of research in this field.
Methods: In this approach, we explored data related to publication metrics, public perceptions, scientific conference, mobile apps, AI tools, and new medications. This was done using a set of keywords, including "Non-alcoholic fatty liver disease," "Metabolic dysfunction-associated steatotic liver disease," "Mobile application," and "Artificial intelligence."
Results and Conclusion: This research highlights significant scientific advances in the field of MASLD, including major scientific meetings, highly cited publications, and the latest FDA-approved therapies. In addition, it examines emerging digital tools and public search frameworks, providing a structured picture of recent developments. These findings provide a comprehensive view of the dynamic MASLD research landscape and emphasize the roles of AI, mobile apps, and emerging therapies in its management.

Keywords

Artificial Intelligence
Fatty Liver Disease
Mobile Application
Metabolic Dysfunction-Associated Steatotic Liver Disease
Non-alcoholic Fatty Liver Disease

Subjects

  1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. [DOI:10.1002/hep.29367] [PMID]
  2. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-61. [DOI:10.1016/S2468-1253(22)00165-0] [PMID]
  3. Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32-s42. [DOI:10.3350/cmh.2022.0365] [PMID] [PMCID]
  4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-47. [DOI:10.1097/HEP.0000000000000004] [PMID] [PMCID]
  5. Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol. 2022;28(4):841-50. [DOI:10.3350/cmh.2022.0239] [PMID] [PMCID]
  6. Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol. 2022;76(4):771-80. [DOI:10.1016/j.jhep.2021.10.025] [PMID]
  7. Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024;65(1):100485. [DOI:10.1016/j.jlr.2023.100485] [PMID] [PMCID]
  8. Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. [DOI:10.1053/j.gastro.2019.11.312] [PMID]
  9. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. [DOI:10.1097/HEP.0000000000000520] [PMID] [PMCID]
  10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. [DOI:10.1002/hep.20701] [PMID]
  11. [Available from: https://www.aasld.org/the-liver-meeting/zobair-m-younossi
  12. Rohit Loomba, MD, MHSc July 16, 2024 [Available from: https://gastroenterology.ucsd.edu/research/labs/fatty-liver/team/loomba/index.html
  13. 2023 N-. AASLD [Available from: https://www.medscape.com/viewcollection/37345
  14. AASLD Nov / 15-19 / 2024 [Available from: https://www.medscape.com/viewcollection/37656
  15. EASL June / 21-24 / 2023 [Available from: https://www.healio.com/news/gastroenterology/20230713/easl-congress-2023-rewind-what-you-may-have-missed-alcohol-use-nash-data-top-agenda
  16. June / 5-8 / 2024.
  17. Global Fatty Liver Day July 14, 2024 [Available from: https://globalfattyliverday.com/
  18. Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. JAMA Intern Med. 2019;179(9):1262-71. [DOI:10.1001/jamainternmed.2019.2248] [PMID] []
  19. NHS App - Apps on Google Play July 27, 2024 [Available from: https://play.google.com/store/apps/details?id=com.nhs.online.nhsonline
  20. Noom: Weight Loss & Health - Apps on Google Play July 27, 2024 [Available from: https://play.google.com/store/apps/details?id=com.wsl.noom
  21. Alkhouri N, Edwards K, Berman M, Finn H, Escandon R, Lupinacci P, et al. A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastro Hep Adv. 2024;3(1):9-16. [DOI:10.1016/j.gastha.2023.08.019] [PMID] []
  22. T. Better Therapeutics wins breakthrough status for health app to treat liver disease.: MedTech Dive 2024 Feb 21 [Available from: https://www.medtechdive.com/news/better-therapeutics-breakthrough-liver-disease/708034/
  23. Kwon OY, Lee MK, Lee HW, Kim H, Lee JS, Jang Y. Mobile App-Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial. J Med Internet Res. 2024;26:e49839. [DOI:10.2196/49839] [PMID] []
  24. Stine JG, Rivas G, Hummer B, Duarte-Rojo A, May CN, Geyer N, et al. Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH. Hepatol Commun. 2023;7(4). [DOI:10.1097/HC9.0000000000000052]
  25. Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, et al. Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. Am J Gastroenterol. 2023; 118(8):1365-72. [DOI:10.14309/ajg.0000000000002143] [PMID] []
  26. Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021;8(2):e188-e94. [DOI:10.7861/fhj.2021-0095] [PMID] []
  27. Aggarwal P, Alkhouri N. Artificial Intelligence in Nonalcoholic Fatty Liver Disease: A New Frontier in Diagnosis and Treatment. Clin Liver Dis (Hoboken). 2021;17(6):392-7. [DOI:10.1002/cld.1071] [PMID] [PMCID]
  28. Liu C, Zhou SH, Su H, Yang WQ, Lu J. An Artificial Neural Network Model Combined with Dietary Retinol Intake from Different Sources to Predict the Risk of Nonalcoholic Fatty Liver Disease. Biomed Environ Sci. 2023 Dec 20;36(12):1123-1135. [DOI: 10.3967/bes2023.120] [PMID]
  29. Ratziu V, Francque S, Behling CA, Cejvanovic V, Cortez-Pinto H, Iyer JS, et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology. 2024;80(1):173-85. [DOI:10.1097/HEP.0000000000000723] [PMID] [PMCID]
  30. Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-28. [DOI:10.1038/s41591-023-02603-1] [PMID] [PMCID]
  31. Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79(4):888-97. [DOI:10.1016/j.jhep.2023.05.013] [PMID]
  32. Ratziu V, Harrison SA, Loustaud-Ratti V, Bureau C, Lawitz E, Abdelmalek M, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. J Hepatol. 2023;78(3):479-92. [DOI:10.1016/j.jhep.2022.10.023] [PMID]
  33. Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, et al. Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2023;108(12):e1542-e50. [DOI:10.1210/clinem/dgad375] [PMID] [PMCID]
  34. Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial. Nat Commun. 2023;14(1):6409. [DOI:10.1038/s41467-023-42162-0] [PMID] [PMCID]
  35. Saxena AR, Lyle SA, Khavandi K, Qiu R, Whitlock M, Esler WP, et al. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes Obes Metab. 2023;25(4):992-1001. [DOI:10.1111/dom.14946] [PMID]
  36. Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol. 2023;78(5):914-25. [DOI:10.1016/j.jhep.2023.02.004] [PMID]
  37. Rinella ME, Lieu HD, Kowdley KV, Goodman ZD, Alkhouri N, Lawitz E, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024;79(3):674-89. [PMID] [PMCID] [DOI:10.1097/HEP.0000000000000607]
  38. Dellinger RW, Holmes HE, Hu-Seliger T, Butt RW, Harrison SA, Mozaffarian D, et al. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. Hepatology. 2023;78(3):863-77. [DOI:10.1002/hep.32778] [PMID]
  39. Siyal M, Abbas Z, Qadeer MA, Saeed A, Ali U, Khatoon A. Misoprostol for non-alcoholic steatohepatitis: a randomised control trial. BMJ Open Gastroenterol. 2024;11(1). [DOI:10.1136/bmjgast-2023-001342] [PMID] [PMCID]
  40. Shi M, Zhang H, Wang W, Zhang X, Liu J, Wang Q, et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Diabetes Complications. 2023; 37(10):108610. [DOI:10.1016/j.jdiacomp.2023.108610] [PMID]
  41. Khaliq A, Badshah H, Shah Y, Rehman IU, Khan KU, Ming LC, et al. The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial. Medicine (Baltimore). 2024;103(45):e40356. [DOI:10.1097/MD.0000000000040356] [PMID] [PMCID]
  42. Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, et al. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clin Gastroenterol Hepatol. 2024;22(1):113-23.e9. [DOI:10.1016/j.cgh.2023.04.012] [PMID]
  43. Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080-93. [DOI:10.1016/S2468-1253(23)00272-8] [PMID]
  44. Nagao M, Sasaki J, Tanimura-Inagaki K, Sakuma I, Sugihara H, Oikawa S. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovasc Diabetol. 2024;23(1):56. [DOI:10.1186/s12933-024-02149-7] [PMID] [PMCID]
  45. Wang X, Lyu L, Li W, Xu L, Zhang H, Wang S, et al. Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial. Diabetes Metab Syndr. 2024;18(9):103126. [DOI:10.1016/j.dsx.2024.103126] [PMID]
  46. Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023; 8(6):511-22. [DOI:10.1016/S2468-1253(23)00068-7] [PMID]
  47. Shankar SS, Daniels SJ, Robertson D, Sarv J, Sánchez J, Carter D, et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. 2024;22(9):1847-57.e11. [DOI:10.1016/j.cgh.2024.04.017] [PMID]
  48. Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7-17. [DOI:10.1016/j.jhep.2024.07.006] [PMID]
  49. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-48. [DOI:10.1038/s41591-024-03018-2] [PMID] [PMCID]
  50. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. [DOI:10.1056/NEJMoa2401943] [PMID]
Iranian Journal of Pathology
Volume 20, Issue 4
Summer 2025
Pages 355-366

  • Receive Date 10 April 2025
  • Revise Date 20 May 2025
  • Accept Date 13 May 2025

Home

Guide for Authors

Submit Manuscript

Contact Us